Current trends in antithrombotic drug and device development

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue SUPPL. 1, 1996, Pages 3-8

  Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet; Antithrombotic drugs; Biotechnology; Heparin; Hirudin,

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; WARFARIN;

ANGIOPLASTY; ATHERECTOMY; BIOTECHNOLOGY; CLINICAL TRIAL; COMPRESSION THERAPY; DEVICE; DRUG DELIVERY SYSTEM; DRUG MONITORING; HEMODILUTION; HUMAN; LASER; PRIORITY JOURNAL; REVIEW; STENT; THROMBOGENESIS; THROMBOSIS; ULTRASOUND THERAPY;

COMBINED MODALITY THERAPY; DRUG MONITORING; FIBRINOLYTIC AGENTS; HUMANS; THROMBOSIS;

EID: 0029759105     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Fareed J, HL Messmore, EW Bermes Jr: New perspectives in coagulation testing. Clin Chem 26:1380-1391, 1980.
2. Fareed J: New methods in hemostatic testing. In: Fareed J (Ed): Perspectives in Hemostasis. Pergamon Press, New York, 1981, pp 310-348.
3. Fareed J, RL Bick, G Squillaci, JM Walenga, EW Bermes Jr: Molecular markers of hemostatic disorders: Implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem 29:1641-1658, 1983.
4. Fareed J, JM Walenga: Current trends in hemostatic testing. Semin Thromb Hemostas 9:379-391, 1983.
5. Fareed J, HL Messmore, JM Walenga, EW Bermes Jr: Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemostas 8:288-301, 1983.
6. Fareed J, JM Walenga, RL Bick, HL Messmore: Low molecular weight markers of hemostatic defects: Impact of automation on the quantitation of hemostatic disorders. Semin Thromb Hemostas 9: 354-378, 1983.
7. Fareed J, A Kumar, JM Walenga, RM Emanuele, K Williamson, D Hoppensteadt: Antithrombotic actions and pharmacokinetics of heparin fragments. Nouv Rev Fr Hematol 26:267-275, 1984.
8. Fareed J: Heparin, its fractions, fragments and derivatives. Semin Thromb Hemostas 11:1-9, 1985.
9. Fareed J: Development of heparin fractions: Some overlooked considerations. Semin Thromb Hemostas 11:227-236, 1985.
10. Fareed J, JM Walenga: Biochemical and pharmacological considerations in the development of heparin and its depolymerized derivatives. Med J Australia 144:21-30, 1986.
11. Fareed J, WH Baker, A Hayes, JM Walenga: Molecular markers of hemostatic activation in established atherosclerosis. Semin Thromb Hemostas 12:102-109, 1986.
12. Fareed J, WH Baker, JM Walenga, HL Messmore: Molecular markers of pathophysiological activation of hemostasis: Current perspectives and future trends. In: Ulutin ON, H Vinazzer (Eds): Thrombosis and Hemorrhagic Diseases. Gozlem Matbaachk Koll. Sto., Istanbul, Turkey, 1986, pp 83-88.
13. Fareed J, J Walenga, K Breddin, JP Caen (Eds): Newer avenues in antithrombotic therapy. Semin Thromb Hemostas 15:237-488, 1989.
14. Hull R, J Hirsh: Long term anticoagulant therapy in patients with venous thrombosis. Arch Intern Med 143:2061-2063, 1983.
15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 13:349-360, 1988.
16. Markwardt F: Pharmacology of hirudin: One hundred years after the first report of the anticoagulant agent. Biophys Biochim Acta 44:1007-1013, 1985.
17. Markwardt F: Pharmacological approaches to thrombin regulation. Ann NY Acad Sci 485:204-214, 1986.
18. Markwardt F, E Fink, B Kaiser, HP Klöcking, G Nowak, M Richter, J Stürzebecher: Pharmacological survey of recombinant hirudin. Pharmazie 43:202-207, 1988.
19. Messmore HL, JM Walenga, F Fareed: Molecular markers of platelet activation. Semin Thromb Hemostas 10:264-269, 1984.
20. Lagerstedt CI, B Fagher, C Olsson, BW Oqvist: Need for long-term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 2:515-518, 1985.
21. Petitti DB, B Strom, K Melmon: Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 81:255-259, 1986.
22. Suarez CR, J Fareed, P Tomich: Neonatal and natural hemostasis: Value of molecular markers in the assessment of hemostastic status. Semin Thromb Hemostas 10:280-284, 1984.
23. Summaria L, JA Caprini, R McMillan, J Sandesara, CA Axelrod, ME Mueller, JP Vagher, J Walenga, J Fareed: Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. Am Surg 54:156-160, 1988.
24. Ulutin ON, J Fareed, A Kumar, JM Walenga, D Hoppensteadt: Pharmacologic profiling of the action of defibrotide in animal models of hemostatic and thrombotic disorders. In: Ulutin ON, H Vinazzer (Eds): Thrombosis and Hemorrhagic Diseases. Gozlem Matbaachk Koll. Sto., Istanbul, Turkey, 1986, pp 101-110.
25. Walenga JM, J Fareed, HL Messmore: Newer avenues in the monitoring of antithrombotic therapy: The role of automation. Semin Thromb Hemostas 9:346-354, 1983.
26. Walenga JM, J Fareed, D Hoppensteadt, RM Emanuele: Laboratory monitoring of heparin: Old vs. new methods. CRC Critical Rev Lab Sci 22:361-389, 1986.